Two people born on the same day can be separated by nearly twenty years of biology. One may carry the molecular wear of a smoker with chronic inflammation and failing kidneys; the other may show the physiology of someone a decade younger. Chronological age, the number we celebrate on birthdays, is a poor proxy for this reality. A sweeping new review in the British Journal of Biomedical Science argues that artificial intelligence is now the decisive tool for closing the gap between the age on your birth certificate and the age of your body — but it also warns that the field is racing ahead on foundations that are still shaky.
The review, led by Guangjun Wang and colleagues at Anqing Normal University, Shanghai University of Traditional Chinese Medicine and Xiangyang Central Hospital, synthesizes the entire pipeline of AI-driven biological age (BA) prediction: which biomarkers feed the models, how engineers transform raw omics and imaging data into learnable features, which algorithms dominate, how systematic bias is corrected, and how performance is judged. Its central message is technical but consequential: aging is not a single number. It is an asynchronous process in which the brain, blood vessels, kidneys and immune system each age at their own rate, and only modern machine learning — particularly deep learning and multimodal fusion — has the capacity to model such nonlinear, system-specific trajectories.
The biological raw material for these models spans a continuum. At the molecular tier sit DNA methylation clocks — Horvath, Hannum, PhenoAge and GrimAge — which read chemical tags on the genome and remain the most accurate single-modality estimators of biological aging, showing robust associations with mortality, disease risk and healthspan. Telomere length reflects replicative senescence; transcriptomic and metabolomic signatures capture age-related shifts in gene regulation and metabolism, with machine learning models trained on multi-omic data reaching prediction errors of roughly four to five years. At the system tier, blood-based panels — inflammatory markers such as C-reactive protein and interleukins capturing the phenomenon of inflammaging, alongside metabolic, hepatic, renal and hematologic indices — are transformed into BA estimates by statistical methods like the Klemera–Doubal method and by deep learning blood clocks, typically within about five years of error.
Imaging adds an organ-specific dimension that molecular clocks cannot provide. Brain MRI models quantify cortical thinning, gray and white matter degradation and network disorganization, with deep learning architectures achieving mean absolute errors as low as two to three years and strong links to cognitive decline. Dental and skeletal X-rays quantify mineralized tissue aging; facial imaging captures cutaneous and craniofacial aging shaped by lifestyle; and retinal photographs offer a non-invasive window into microvascular and neural aging, scalable for population screening. These modalities are ideal for AI precisely because they are high-dimensional and plentiful — the kind of data convolutional neural networks and transformers were built to digest.
Feature engineering, the review stresses, is not a mere preprocessing chore but a design decision that determines whether a model can capture asynchronous aging at all. High-dimensional methylation loci and metabolomic profiles require normalization and batch-effect mitigation; principal component analysis and autoencoders distill compact latent factors from noisy omics; classical screens such as correlation with chronological age, Cox proportional hazards regression and variance inflation factor diagnostics still underpin transparent, clinically intuitive biomarker panels. The AI shift comes with representation learning: variational autoencoders learn noise-robust embeddings, graph neural networks model biomarker dependencies such as gene co-expression networks, and attention-based transformers learn feature importance dynamically — architectures well suited to encoding organ-specific representations and fusing them into a unified estimate that respects differential aging rates across subsystems.
On the modeling side, the field has progressed from weighted regression schemes like the Klemera–Doubal method — interpretable but constrained by linear assumptions — through random forests, support vector machines and elastic net regression, to deep architectures that learn aging representations end-to-end. The milestones are striking. DeepMAge, a neural network epigenetic clock trained on more than 4,000 blood methylomes, achieved a mean absolute error of 2.77 years, outperforming regression baselines. In neuroimaging, a global–local transformer framework reduced brain age error to 2.7 years. Multimodal transformers now integrate methylation, transcriptomic and imaging signals; contrastive learning disentangles aging signals from confounding noise; and multitask learning jointly predicts BA alongside sex, disease risk or mortality to improve regularization and transferability.
Yet raw accuracy is not enough, and the review devotes unusual care to model correction — the post-prediction step that separates a publishable number from a clinically trustworthy one. Uncorrected BA models systematically overestimate age in younger individuals and underestimate it in older ones, the notorious age–delta correlation or regression-to-the-mean problem. Skewed loss functions penalize these asymmetric errors during training, as in the AccelerAge framework, where gradient magnitudes adapt to a subject’s age and error direction, driving residual–age correlations toward zero on Cam-CAN and ABIDE neuroimaging datasets. AgeML performs transparent linear recalibration of predicted against true age; z-score correction standardizes outputs to population-level means and variances; and risk-difference methods define BA relative to expected age-dependent physiological profiles, as in vascular age frameworks built from radial artery pulse waves.
Evaluation is equally two-sided. The data perspective leans on mean absolute error, RMSE and the coefficient of determination — deep learning models in neuroimaging and multimodal settings now routinely achieve RMSE below three to four years. But high numerical performance does not guarantee biological validity. The knowledge perspective asks whether BA deltas — the gap between predicted and chronological age — track real health differences: cross-sectional analyses link accelerated aging to disease, frailty and socioeconomic conditions, while longitudinal cohort studies, the stronger test, show that BA acceleration predicts cognitive impairment, multimorbidity and mortality. Electronic health records extend this validation to population scale, with AI-predicted ECG age gaps correlating with mortality and cardiovascular risk after bias adjustment.
The challenges, however, are formidable, and the review is candid about them. Biomarker panels vary wildly across studies, limiting reproducibility; aggregating heterogeneous signals into a single BA output can obscure organ-level aging patterns. Most supervised models train against chronological age, implicitly assuming that deviations from CA reflect true aging — an assumption that can bias models toward chronological patterns rather than aging mechanisms and invites overfitting. Deep models function as black boxes, complicating clinical acceptance where interpretability and causal insight are prerequisites. Cross-sectional studies dominate the literature but cannot capture temporal trajectories or asynchronous dynamics. And most current models ignore genotype altogether: variants in APOE and FOXO3 demonstrably modulate aging trajectories — the APOE4 allele is linked to faster biological aging while FOXO3 polymorphisms show reproducible longevity associations — yet polygenic risk scores and longitudinal clinical history are rarely built into model architectures, risking the conflation of disease burden with intrinsic aging.
The path forward, the authors argue, requires standardized preprocessing protocols, robust validation across demographically diverse populations, interpretable and bias-aware AI, and above all the integration of multi-omics and longitudinal datasets into frameworks that model aging as the multidimensional, asynchronous process it is. If the field succeeds, biological age could graduate from a descriptive curiosity — the number behind longevity headlines — into a clinically actionable metric: a system-level dashboard of how fast each of your organs is aging, and a target for interventions that might slow it. The machines are already reading the clock. The task now is to make sure they are reading it fairly, transparently and in a way that changes what happens in the clinic.
Subject of Research: AI biological age prediction review
Article Title: Artificial intelligence approaches in biological age prediction: current status and challenges
Article References: Wang, G., Ding, P., Li, Z., Tang, Q., Tu, L., Jiang, T., Zhang, L., Su, B., Xu, J., & An, H. (2026). Artificial intelligence approaches in biological age prediction: current status and challenges. British Journal of Biomedical Science, 83, Article 16141. https://doi.org/10.3389/bjbs.2026.16141
Image Credits: AI Generated
Keywords: aging, artificial intelligence, biological age, epigenetic clocks, deep learning, precision medicine, Artificial, intelligence, approaches, biological, prediction, current
News Source: Blake Davidson. (October 17, 2026). AI aging clocks: how machines learn to measure how fast you are really aging. Scienmag.
